P. Ferré

发表

Better characterization of vinflunine pharmacokinetics variability and exposure/toxicity relationship to improve its use: Analyses from 18 trials

L. Nguyen, Antonin Schmitt, G. Zorza, 2018, British journal of clinical pharmacology.

Phase I and Pharmacokinetic Study of IV Vinflunine in Combination With Carboplatin in Chemonaive Patients With Advanced Non-small Cell Lung Cancer

C. Tournoux-Facon, G. Robinet, P. Ferré, 2012, American journal of clinical oncology.

Metronomic treatment of advanced non-small-cell lung cancer with daily oral vinorelbine – a Phase I trial

J. von Pawel, R. Huber, S. Guetz, 2017, OncoTargets and therapy.

Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma

M. Macro, X. Leleu, T. Facon, 2018, Oncotarget.

Effect of ethnicity on vinorelbine pharmacokinetics: a population pharmacokinetics analysis

Xiaoyan Chen, D. Zhong, Zhang Li, 2019, Cancer Chemotherapy and Pharmacology.

Randomized, double-blind trial of F14512, a polyamine-vectorized anticancer drug, compared with etoposide phosphate, in dogs with naturally occurring lymphoma

A. Duhamel, B. Gomes, Zacharie Segaoula, 2020, Oncotarget.

Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth

P. Validire, C. Sautès-Fridman, F. Petitprez, 2019, Cancer Immunology Research.

F14512, a polyamine-vectorized inhibitor of topoisomerase II, exhibits a marked anti-tumor activity in ovarian cancer.

J. Annereau, C. Bailly, A. Kruczynski, 2016, Cancer letters.

Translational Medicine Case Studies and Reports

L. Audoly, P. Ferré, A. Passioukov, 2016 .

Phase I Clinical Pharmacology Study of F14512, a New Polyamine-Vectorized Anticancer Drug, in Naturally Occurring Canine Lymphoma

X. Thuru, L. Nguyen, B. Gomes, 2015, Clinical Cancer Research.

504 PVRIG, a novel T cell checkpoint, is preferentially expressed in TLS on stem-like memory T cells, potentially inhibiting their expansion

Y. Turpaz, Amit Novik, E. Ophir, 2022, Regular and Young Investigator Award Abstracts.

A phase 1 study of vinflunine in combination with trastuzumab for the treatment for HER2-positive metastatic breast cancer

R. Paridaens, H. Wildiers, O. Rixe, 2012, Cancer Chemotherapy and Pharmacology.

Phase I and pharmacokinetic study of IV vinflunine in cancer patients with liver dysfunction

A. Ravaud, P. Fumoleau, F. Saliba, 2013, Investigational New Drugs.

Vinflunine Oral Pharmacokinetics and Absolute Bioavailability of Soft and Hard Gelatin Capsules

J. Delord, J. Bennouna, P. Ferré, 2012, Clinical Pharmacokinetics.

Phase I dose-escalation study of vinflunine hard capsules administered twice a day for 2 consecutive days every week in patients with advanced/metastatic solid tumors

J. Cortés, J. Vermorken, E. Calvo, 2012, Cancer Chemotherapy and Pharmacology.

A randomised, multicentre open-label phase II study to evaluate the efficacy, tolerability and pharmacokinetics of oral vinorelbine plus cisplatin versus intravenous vinorelbine plus cisplatin in Chinese patients with chemotherapy-naive unresectable or metastatic non-small cell lung cancer.

Jian-hua Chang, M. Riggi, Y. Shu, 2019, Journal of thoracic disease.

315 W0180 novel anti-VISTA antibody: Rationale for target patient population and first-in-human trial design in monotherapy and in combination with anti-PD1 antibody

I. Melero, A. Marabelle, C. Gomez-Roca, 2020, Journal for ImmunoTherapy of Cancer.